Skip to main content

Table 1 Patients characteristics

From: Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy

Patient ID#

Sex

Age (Year)a

Site

Relapse time (months)b

Chemotherapy/Length(months)c

Survival

Control patients

 1

M

5

Spinal Cord

27

 

Alive

 2

M

11

Spinal Cord

30

 

Deceased

 3

M

2

Cerebellum

31

 

Alive

 4

M

11/12

Cerebellum

8

 

Alive

 5

F

4

Left Thalamic

19

 

Alive

 6

M

16

Left intraventricular

58

 

Alive

 7

F

13

Right Front Lobe

20

 

Alive

 8

F

5

Right lateral ventricle subependymal

107

 

Alive

Investigative patients

 9

M

4

Cerebellum

8

CPL, VIN/12, TPCV/14

Alive

 10

M

3

Left Temporal Lobe

13

CPL/4, VCR/4, VIN/10

Alive

 11

F

4

Right Temporal Lobe

8

CPL/8, VCR/8

Alive

 12

F

7

Spinal Cord

12

CPL/7, VCR/7, ISP/4

Deceased

 13

F

1

Suprasellar/Third ventricle

46

CPL, VCR/4, VIN/9, O6-BG & TMZ/2

Deceased

 14

F

1

C4-T4 spinal cord

27

CPL, VCR, TMZ/12

Alive

 15

M

7/12

Posterior Fossa

10

CPL, ETO, TAM/10

Deceased

  1. aAge at initial diagnosis
  2. bTime of relapse after first operation
  3. cInitial chemotherapy/length of treatment (months) after first operation
  4. Abbreviations: M male, F female, CPL carboplatin, VCR vincristine, VIN vinblastine, TPCV Thioguanine, Procarbazine, CCNU and Vincristine, ISP ispinesib, ETO etoposide, TAM tamoxifen, O 6 -BG O6-Benzylguanine, TMZ temozolomide